Ascentage Pharma’s Olverembatinib Earns Breakthrough Designation for SDH-Deficient GIST
The China’s Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) to olverembatinib,...
Bayer
Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023,...
Bayer Reports 2022 Sales Growth, Highlights New Drug Performances
Germany-based Bayer (ETR: BAYN) released its 2022 annual report this week, revealing a global sales...
Hua Medicine Receives Milestone Payment from Bayer for Dorzagliatin
China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment...
3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status...
Hope Medicine Gains Global Approval for Phase II Trial of HMI-115
China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II...
Hengrui Pharmaceuticals Receives FDA ANDA Approval for Gadobutrol Generic
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving Abbreviated New Drug Application (ANDA) status...
Yabao Receives FDA Clearance for Generic Nexavar
China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received Abbreviated...
Shandong Xinhua and Bayer Announce Strategic Partnership at CIIE
A strategic partnership between China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) and Bayer Consumer...
Innovent’s Parsaclisib Filed for Marketing Approval in China
China’s Center for Drug Evaluation (CDE) has received a marketing approval application for Innovent Biologics...
Bayer to Set Up Shenzhen Unit to Boost Women’s Healthcare in South China
Bayer’s (ETR: BAYN) women’s healthcare unit for the South China region is reportedly planning to...
Bayer AG’s Q2 2022 Results Show Global Sales Growth Amid China VBP Pressures
Germany-based pharmaceutical giant Bayer AG (VIE: BAYN) released its Q2 2022 financial report, revealing a...
Bayer’s Kerendia Approved by China’s NMPA for Diabetic Kidney Disease
The National Medical Products Administration (NMPA) has approved Bayer’s (ETR: BAYN) Category 1 drug Kerendia...
Bayer Initiates US Recall of TRK Inhibitor Vitrakvi Due to Mold Contamination
Germany-based Bayer (ETR: BAYN) has announced a voluntary recall of a specific lot of its...